



March 8, 2017

Tandem Diabetes Care Announces Plans for Improved Infusion Set Connector Developed from Customer Feedback

SAN DIEGO--(BUSINESS WIRE)-- Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced plans to implement a new infusion set connector for Tandem insulin pump cartridges and infusion sets, the t:lock™ Connector. Consistent with the philosophy followed for the development of all of Tandem's products, the t:lock Connector was designed based on direct customer feedback related to the process for filling the infusion set with insulin. The new design reduces the time required to fill the infusion set tubing by approximately 30 seconds and reduces the amount of insulin used in the process by approximately four and a half units.

"We strive to continue improving our products based on customer feedback, and the length of our cartridge change process has consistently been among the top requests," said Kim Blickenstaff, President and CEO of Tandem Diabetes Care. "The new t:lock Connector looks and feels like the current connector, but improves the overall experience of changing the cartridge."

All the infusion sets currently offered by Tandem Diabetes Care will be made available with the new t:lock Connector. The new infusion sets will have the same insurance coverage as current sets.

Tandem expects to begin a gradual roll out of the new t:lock Connector in the second half of 2017. The Company plans to offer both the current connector as well as the t:lock Connector through the end of the year to make the transition as smooth as possible for existing customers. Current Tandem pump users will be contacted by Tandem or their current supplies distributor with more information closer to the time of availability.

About Tandem Diabetes Care, Inc.

Tandem Diabetes Care, Inc. (www.tandemdiabetes.com) is a medical device company with an innovative, user-centric and integrated approach to the design, development and commercialization of products for people with diabetes who use insulin. The Company manufactures and sells the t:slim X2™ Insulin Pump, the slimmest and smallest durable insulin pump currently on the market; the t:flex® Insulin Pump, the first pump designed for people with greater insulin requirements; and the t:slim G4™ Insulin Pump, the first continuous glucose monitoring-enabled pump with touchscreen simplicity. Tandem is based in San Diego, California.

Follow Tandem Diabetes Care on Twitter @tandemdiabetes; use #tslimX2, #tslimG4, #tflex, #tconnect and \$TNDM.

Follow Tandem Diabetes Care on Facebook at www.facebook.com/TandemDiabetes.

Follow Tandem Diabetes Care on LinkedIn at <https://www.linkedin.com/company/tandemdiabetes>.

t:slim, t:flex and Tandem Diabetes Care are registered trademarks, and t:slim X2, t:slim G4 and t:lock are trademarks of Tandem Diabetes Care, Inc. All other trademarks are the property of their respective owners.

Forward-Looking Statement

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. These forward-looking statements include statements regarding the timing of the rollout of the t:lock Connector and the Company's expectations that the t:lock Connector will improve the overall experience of changing a cartridge. The Company's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties. For instance, the infusion set compatible with the t:lock Connector may not gain the regulatory approvals required for launch, the Company may be unable to manufacture the t:lock cartridge and infusion set at volumes necessary to support the needs of its existing and future customers, the anticipated rollout period may take longer than anticipated, and the Company may not ultimately be able to gain market acceptance for the t:lock Connector. In addition, the Company's results may be impacted by the other risks identified in the Company's most recent Annual Report on Form 10-K, and other documents that the Company files with the Securities and Exchange Commission. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Tandem undertakes no obligation to update or review any forward-looking statement in this press release because of new

information, future events or other factors.

View source version on [businesswire.com](http://www.businesswire.com): <http://www.businesswire.com/news/home/20170308005276/en/>

For Tandem Diabetes Care, Inc.

Media Contact:

Steve Sabicer, 714-907-6264

ssabicer@thesabicergroup.com

or

Investor Contact:

Susan Morrison, 858-366-6900 x7005

smorrison@tandemdiabetes.com

Source: Tandem Diabetes Care, Inc.

News Provided by Acquire Media